Mr. Evan Levine reports

PSYBIO THERAPEUTICS ANNOUNCES EXPANSION OF PATENT PORTFOLIO WITH ADDITIONAL GLOBAL PATENT APPLICATIONS

Psybio Therapeutics Corp. has filed additional international patent applications in Europe, Africa and Asia. This brings Psybio's total number of patent application submissions to 20, making it one of the most robust portfolios in the sector.

"Biosynthetic tryptamine production allows the development of psycho-targeted molecules as novel therapeutic candidates, with the goal to potentially help improve human health," stated Michael Spigarelli, MD, PhD, MBA, Psybio's chief medical officer. "Our IP [intellectual property] strategy fosters the developmental processes and will allow us to develop these molecules as smoothly and rapidly as possible. Global patent submissions further expand Psybio's IP portfolio and support our ongoing plans for growth."

The patent applications submitted comprise advancements concerning production methodology, host strains and processes of production that support and allow Psybio's novel production methodology to be globally protected. These filings demonstrate the company's commitment to value creation, while also promoting scientific and methodologic advancements in the field.

"Psybio is dedicated to leading the development of psycho-targeted therapeutic candidates in our vision to potentially improve mental and neurological health," stated Evan Levine, Psybio's chief executive officer. "With these additional patent submissions, Psybio continues to demonstrate its leadership in the biosynthetic development field by prioritizing intellectual property protection, which is necessary for us to achieve our business objectives and important for our current and future investors."

About Psybio Therapeutics Corp.

Psybio Therapeutics is an intellectual property driven biotechnology company developing new bespoke psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering, as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently continuing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines, and combinations thereof.

We seek Safe Harbor.